We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Substance P Antagonist Aprepitant Shows no Additive Effect Compared with Standardized Topical Treatment Alone in Patients with Atopic Dermatitis.
- Authors
LÖNNDAHL, Louise; HOLST, Mikael; BRADLEY, Maria; KILLASLI, Hassan; HEILBORN, Johan; HALL, Martin A.; THEODORSSON, Elvar; HOLMBERG, Jadwiga; NORDLIND, Klas
- Abstract
Atopic dermatitis (AD) is a chronic, itchy, inflammatory skin disorder that may worsen due to stress and anxiety. Tachykinins have been suggested to be involved in the inflammation in AD, as well as pruritus. Aprepitant is a NK-1 receptor antagonist. This open randomized trial evaluated the effect of aprepitant added to topical treatment in adult patients with moderate-severe AD. The treatment group (n = 19) received 80 mg/day aprepitant for 7 days as a supplement to standardized topical treatment with a moderately strong steroid and a moisturizer. The control group (n = 20) received topical treatment alone. Patients were monitored for the extent of the disease (using SCORing of Atopic Dermatitis; SCORAD), pruritus, and scratching movements. In both the aprepitant-treated and the control groups there was a decrease in SCORAD, pruritus and scratching movements. However, there was no significant additional improvement in any of these parameters in the aprepitant-treated group compared with the control group.
- Subjects
SUBSTANCE P antagonists; ATOPIC dermatitis; SKIN disease treatment; OINTMENTS; STEROID drugs; COMPARATIVE studies; PATIENTS
- Publication
Acta Dermato-Venereologica, 2018, Vol 98, Issue 3, p324
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-2852